Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats

Bajić, Zorislava; Sobot, Tanja; Uletilović, Snežana; Mandić-Kovačević, Nebojša; Cvjetković, Tanja; Malicevic, Ugljesa; Đukanović, Đorđe; Duran, Mladen; Vesić, Nikolina; Avram, Sanja; Jovicic, Sanja; Katana, Maja; Matavulj, Amela; Ponorac, Nenad; Djurić, Dragan; Stojiljković, Miloš P.; Škrbić, Ranko

doi:10.1139/cjpp-2022-0534

Cited by 4 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have demonstrated the efficacy of liraglutide in preventing and treating vascular complications of diabetes and alleviate myocardial damage. [13,14] However, the impact of liraglutide on cardiac function in patients with type 2 diabetes remains uncertain. While certain studies have demonstrated the potential of liraglutide in enhancing indicators of cardiac function, others have yielded inconclusive results regarding any significant improvement.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials

Xia,

Yu,

Lei

et al. 2024

Medicine

View full text Add to dashboard Cite

Background: Liraglutide widely utilized in type 2 diabetes treatment, has elicited conflicting findings regarding its impact on cardiac function in patients with this condition. Therefore, The objective of this study was to conduct a meta-analysis of randomized controlled trials (RCTs) to evaluate the effects of liraglutide on cardiac function in patients diagnosed with type 2 diabetes. Methods: We identified double-blind randomized trials assessing the effects of liraglutide compared to placebo on cardiac function in patients with type 2 diabetes. Data were synthesized with the fixed-effect models to generate standard mean differences (SMDs) with 95% confidence intervals (CIs) of each outcome for liraglutide versus placebo. The risk of bias would be assessed according to the Cochrane Risk of Bias Tool, while meta-analysis would be conducted using Revman 5.3.0 software. The evidence was graded based on the Grading of Recommendations Assessment, Development and Evaluation approach. Results: The meta-analysis encompassed 5 RCTs including 220 participants. Results revealed that liraglutide exhibited significant enhancements in left ventricular ejection fraction [SMD = −0.38, 95%CI(−0.70, −0.06), P = .02], cardiac index [SMD = −1.05, 95%CI(−1.52, −0.59), P < .0001], stroke volume [SMD = −0.67, 95%CI(−1.02, −0.32), P = .0002] and early diastolic filling velocity/late atrial filling velocity ratio [SMD = −0.52, 95%CI(−0.82, −0.22), P = .0006]. However, no statistically significant impact on cardiac output [SMD = −0.20, 95%CI(−0.53, 0.14), P = .26], early diastolic filling velocity/early diastolic annular velocity (E/Ea) ratio [SMD = −0.34, 95%CI(−0.75, 0.06), P = .10] and early diastolic filling velocity/early diastolic mitral annular velocity ratio [SMD = 0.21, 95%CI(−0.15, 0.56), P = .25] was observed. The Grading of Recommendations Assessment, Development and Evaluation evidence quality ratings indicated that all the outcome measures included in this study were evaluated as having low and very low quality. Conclusion: The available evidence suggested that liraglutide may exert a favorable impact on cardiac function in patients with type 2 diabetes. Consequently, the utilization of liraglutide as a preventive measure against heart failure incidents in individuals with type 2 diabetes represents a promising strategy. However, robust evidence support requires the conduct of large-scale, multicenter high-quality RCTs.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Studies have demonstrated the efficacy of liraglutide in preventing and treating vascular complications of diabetes and alleviate myocardial damage. [13,14]…”

Section: Introductionmentioning

confidence: 99%

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials

Xia,

Yu,

Lei

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

Unlocking the miRNA-34a-5p/TGF-β and HMGB1/PI3K/Akt/mTOR crosstalk participate in the enhanced cardiac protection of liraglutide against isoproterenol-induced acute myocardial injury rat model

Abdel-Reheim,

Zaafar,

El-Shoura

et al. 2024

International Immunopharmacology

View full text Add to dashboard Cite

Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus

Alobaid,

Alshahrani,

Alonazi

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

One of the possible candidates for the treatment of diabetic cardiomyopathy is liraglutide, a glucagon-like peptide-1 receptor (GLP1R) agonist. In this study, the impacts of liraglutide on the integrin-linked kinase (ILK)-related PI3K/AKT axis in rats with type 2 diabetes induced via streptozotocin were examined. Twenty-four Wistar albino rats were distributed in four different groups, and a high-fat diet and streptozotocin were used to induce type 2 in two groups. Rats in the untreated control groups were administered 0.9% NaCl solution over a 6-week period, and those in the treatment groups were administered 0.9% NaCl for 3 weeks, followed by subcutaneous injection of liraglutide (150 μg/kg) for an additional 3 weeks. In the liraglutide-treated diabetic group, the heart-to-body weight ratio was significantly reduced, levels of cardiac biomarkers, troponin I and creatine-kinase-MB, were improved; activities of antioxidant enzymes, glutathione peroxidase and superoxide dismutase, were increased; and levels of malondialdehyde were decreased. Western blotting and immunohistochemical studies revealed increased levels of ILK, P-PI3K, P-AKT, and BCL2, as well as those of caspase 3, BAX, and P-PTEN, indicating mitigation of cardiomyocyte apoptosis. Our results show that liraglutide, by targeting GLP1Rs, enhances the expression of proteins in the ILK/PI3K/AKT/PTEN pathway and thereby exerts its cardioprotective effects in rats with DCM.

show abstract

Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats

Cited by 4 publications

References 56 publications

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials

Unlocking the miRNA-34a-5p/TGF-β and HMGB1/PI3K/Akt/mTOR crosstalk participate in the enhanced cardiac protection of liraglutide against isoproterenol-induced acute myocardial injury rat model

Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About